We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · January 04, 2021

AGS-16C3F vs Axitinib in Previously Treated Patients With Metastatic Renal Cell Carcinoma

The Oncologist

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Oncologist
A Randomized Phase II Study of AGS-16C3F Versus Axitinib in Previously Treated Patients With Metastatic Renal Cell Carcinoma
Oncologist 2020 Dec 08;[EPub Ahead of Print], C Kollmannsberger, TK Choueiri, DYC Heng, S George, F Jie, R Croitoru, S Poondru, JA Thompson

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Renal Cell Carcinoma Center of Excellence

Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.


Further Reading